PI3K-delta syndrome; PASLI disease
Jump to navigation
Jump to search
Pathology
Clinical manifestations
- infections
- lymphocyte proliferation (lymphocytosis)
- autoimmunity
- enteropathy
- bronchiectasis
- increased risk of lymphoma
- early mortality
Management
- leniolisib (Joenja) FDA-approved
More general terms
References
- ↑ Rao VK et al A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome Blood. 2023 Mar 2;141(9):971-983 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36399712 PMCID: PMC10163280 Free PMC article